Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP is an autoimmune disorder where the immune system attacks the protective covering of nerves, called myelin, leading to muscle weakness and loss of sensation in the arms and legs. This research is evaluating TAK-411, a modified immune globulin G made from human plasma, to see if it can reduce inflammation and improve symptoms in adults with CIDP. The main goal is to assess how TAK-411 affects physical functioning compared to a placebo group from a previous trial. Participants will receive TAK-411 through intravenous IV infusions. Initially, a 400 mgkg induction dose is given on Day 1, which may be repeated once after 3 weeks if no clinical change is seen. Following this, participants receive 200 mgkg IV infusions every 3 weeks for 24 weeks during the initial treatment period. Afterward, there is an optional extended treatment period lasting an additional 27 weeks. Participants may be treated with TAK-411 for up to 51 weeks and followed for 3 weeks after their last dose. During the study, participants may visit the clinic up to approximately 21 times. Various assessments will track functional ability and neurological status at multiple time points, including weeks 12, 24, and 54. Researchers will monitor changes using measures like the INCAT score, I-RODS score, hand grip strength, and adverse events. Safety and tolerability of TAK-411 will also be evaluated throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effects of the drug EYU688 compared with a placebo in adults aged 18 to 60 who have dengue fever. This study aims to understand how EYU688 influences dengue viral load, fever clearance time, and clinical symptoms. It is a phase 2 randomized, participant- and investigator-blinded, placebo-controlled trial with two parallel cohorts differing by pharmacokinetic sampling schedules. Participants will receive EYU688 or a matching placebo orally. The study includes two cohorts running simultaneously one with intensive pharmacokinetic sampling and one with sparse sampling, to assess the drugs behavior in the body. Treatment is administered during the initial days following fever onset, with careful monitoring of viral load and clinical signs. Throughout the study, participants will undergo regular assessments including viral load measurements, fever monitoring, clinical symptom evaluations, and laboratory tests such as blood counts and liver enzyme levels. Safety monitoring for adverse events will continue through Day 35. The primary outcome is reduction in viral load at 48 hours after treatment start. The total trial period includes follow-up until Day 35, with ongoing evaluation of clinical recovery and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.
Actively Recruiting
Researchers are investigating a multicomponent intervention aimed at improving cognitive function in older adults with mild cognitive impairment and their primary caregivers. This condition is a precursor to dementia and poses risks to both patients and their caregivers, often family members without formal training. The study is a pilot randomized clinical trial designed to generate evidence on the interventions efficacy and applicability, tailored specifically to the Colombian population. The intervention lasts 12 weeks and combines cognitive training, physical exercise, and nutritional counseling for patients, delivered at home twice a week by professionals, along with a recommendation to walk 30 minutes daily. Caregivers participate in weekly group sessions led by healthcare professionals to support their caregiving role. The control group receives usual care, including cognitive rehabilitation and physical therapy, plus educational materials on infectious diseases sent weekly. Participants and their caregivers will be assessed at baseline and followed up at 3, 6, and 9 months. Evaluations include cognitive function tests covering multiple domains, physical frailty, nutritional status, mobility, independence, social support, and caregiver burden. Additionally, a subsample will have their intestinal microbiota composition and APOE gene allele status analyzed before and after the intervention. Attendance and adherence to sessions will be monitored to ensure study compliance.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.
Actively Recruiting
Healthy Volunteer
Breast cancer is a major health concern in Latin America, where it is the most common cancer among women. Women in this region tend to develop breast cancer at a younger age and are often diagnosed at a later stage compared to women in Western countries. Mortality rates have risen rapidly over the past twenty years, making breast cancer the leading cause of cancer death among Latin American women. There is limited knowledge about specific risk factors and tumor characteristics for premenopausal breast cancer in this population, which impacts treatment and survival outcomes. The PRECAMA study is an international, population-based case-control study conducted by the International Agency for Research on Cancer across Mexico, Costa Rica, Colombia, and Chile. It focuses on women aged 20 to 45 years, including both those diagnosed with primary invasive breast cancer and matched controls without cancer living in the same cities. Participants provide detailed questionnaire data on health, reproductive history, lifestyle factors, and diet. Biological samples such as blood and urine are collected, and tumor samples from cases undergo molecular and pathological analyses to characterize breast cancer subtypes. Participants complete standardized interviews and questionnaires, and physical measurements like body weight and height are taken. Researchers collect detailed lifestyle and environmental exposure data alongside biological specimens for biomarker studies. The main outcome is the presence of breast cancer at recruitment. This comprehensive approach aims to improve understanding of risk factors and breast cancer subtypes in young Latin American women to support prevention and public health strategies. The study is ongoing, with participant involvement lasting from recruitment through data collection and analysis phases.
Actively Recruiting
This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.
Actively Recruiting
Researchers are studying the best ways to manage patients with brain arteriovenous malformations AVMs, whether these AVMs have caused bleeding ruptured or not unruptured. The study aims to compare medical conservative management with interventional treatments like neurosurgery, radiation therapy, radiosurgery, and endovascular procedures to see which approach better reduces the risk of death or disabling stroke over 10 years. There is also a nested trial to evaluate whether embolization before surgery or radiosurgery improves treatment success and safety. The interventional therapies studied include surgical removal of the AVM when it is safely operable, radiation therapy for smaller AVMs less than 3 cm that cannot be safely operated on, radiosurgery, and curative embolization. Patients judged by a multidisciplinary team to possibly benefit from endovascular treatment before surgery or radiation may be randomly assigned to receive embolization or not. The conservative group receives medical management for symptoms, and if bleeding or infarction occurs, they may become candidates for interventional therapy. Participants will be followed for up to 10 years to monitor outcomes such as death from any cause or disabling stroke, measured by the Rankin Scale. The study will track neurological events, treatment complications, and the success of AVM occlusion. Researchers will regularly assess participants neurological status and adverse events. This long-term follow-up aims to provide clearer guidance on the safest and most effective management strategies for brain AVMs.